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Abstract
International and national guidelines on the treatment of
chronic nonhypovolaemic hypotonic hyponatraemia differ;
therefore, we have undertaken this systematic review and meta-
analysis to investigate the efficacy and safety of interventions for
the treatment of chronic nonhypovolaemic hypotonic hypona-
traemia. Following registration of the review protocol with
PROSPERO, systematic literature searches were conducted to
identify randomized and quasi-randomized controlled trials
assessing any degree of fluid restriction or any drug treatment
with the aim of increasing serum sodium concentration in
patients with chronic nonhypovolaemic hypotonic hypona-
traemia. Where appropriate, outcome data were synthesized in a
meta-analysis. A total of 45 716 bibliographic records were iden-
tified from the searches and 18 trials (assessing conivaptan, lixi-
vaptan, tolvaptan and satavaptan) met the eligibility criteria.
Results suggest that all four vasopressin receptor agonists (“vap-
tans”) significantly improve serum sodium concentration. Lixi-
vaptan, satavaptan and tolvaptan were associated with greater
rates of response versus placebo. There was no evidence of a dif-
ference between each of the vaptans compared with placebo for
mortality, discontinuation and rates of hypernatraemia. No RCT
evidence of treatments other than the vaptans for hyponatraemia
such as oral urea, salt tablets, mannitol, loop diuretics demeclo-
cycline or lithium was identified. Vaptans demonstrated superi-
ority over placebo for outcomes relating to serum sodium
correction. Few trials documented the potential benefit of vap-
tans on change in health-related quality of life as a result of
treatment. There was also a lack of high-quality RCT evidence
on the comparative efficacy of the vaptans and other treatment
strategies for the treatment of chronic nonhypovolaemic hypo-
tonic hyponatraemia.
(Received 3 May 2016; returned for revision 31 January 2017;
finally revised 13 February 2017; accepted 15 February 2017)
Introduction
Hyponatraemia (HN) serum sodium concentration <135 mmol/l
is the most common disorder of body fluid and electrolyte
imbalance.1–3 It is associated with various clinical conditions1–3
and reportedly occurs in 15–30% of hospital admissions.2,3
Hyponatraemia may be associated with iatrogenic causes or, in
approximately 35% of cases,4 be caused by the kidneys retaining
water because of excess vasopressin secretion.5
The most common noniatrogenic cause of nonhypovolaemic
hypotonic hyponatraemia is the syndrome of inappropriate
antidiuretic hormone secretion (SIADH), a disorder of impaired
water excretion due to the inability to suppress the secretion of
vasopressin resulting in reduced urinary volumes. If water intake
exceeds the reduced urine output, the resulting water retention
leads to the development of hyponatraemia.3,5 Other causes
include excessive fluid intake, excessive solute losses, renal
failure, hormonal abnormalities and low solute intake.3
Nonhypovolaemic hyponatraemia is not a single diagnosis but
a combination of a very heterogeneous group of clinical circum-
stances with variable clinical outcome depending on the hypona-
traemia aetiology. Current treatment of nonhypovolaemic
hyponatraemia depends primarily on ascertaining the underlying
cause and must be undertaken carefully to avoid too rapid an
increase in serum sodium concentration. Overly rapid correction
can result in osmotic demyelination syndrome.3,6 Fluid restric-
tion is generally the first-line treatment for chronic hypona-
traemia in the absence of relevant symptoms, including HN
secondary to SIADH. Hypertonic saline should be administered
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in acute HN and in chronic HN in the presence of severe or
moderate symptoms. However, there is no consensus regarding
the optimal second-line options when fluid restriction is not
appropriate or does not adequately correct the hypona-
traemia.1,3,5 Alternative treatment strategies include oral urea,
salt tablets, mannitol, loop diuretics demeclocycline, lithium and
recently vasopressin receptor antagonists (vaptans).1,3,5
Vaptans block the V2 receptors in the kidney facilitating
aquaresis and restoring serum sodium level through restoration
of normal circulating volume.3,6 Advice in national and interna-
tional guidelines on recommended treatments varies. A number
of national guidelines recommend tolvaptan as a second-line
option for treating hyponatraemia secondary to SIADH when
fluid restriction is unsuitable,3,7,8 but European guidelines in
endocrinology, nephrology and intensive care medicine do not
recommend the use of vaptans for this indication.1,9,10
Given this difference in published guidelines, this systematic
review was undertaken to identify the randomized and quasi-
randomized controlled trial evidence for the effectiveness of
interventions to treat chronic nonhypovolaemic hypotonic
hyponatraemia by assessing outcomes relating to change in
serum sodium concentration, all-cause mortality, health-related
quality of life outcomes, outcomes potentially related to over-
correction of serum sodium concentration, treatment-specific
side effects and treatment discontinuation.
Methods
A systematic review was undertaken according to the principles
of systematic reviewing in the Cochrane handbook.11 Two inde-
pendent clinical experts (not involved in the conduct of the sys-
tematic review) peer-reviewed the protocol, statistical plan and
draft report. The protocol was registered on PROSPERO12
(CRD42015016670).
Studies were eligible for inclusion if they assessed the treat-
ment of patients over 14 years of age. Children (aged 28 days to
14 years) were ineligible because they have significantly different
physiological requirements and clinical circumstances to adults.
Chronic nonhypovolaemic hypotonic hyponatraemia was defined
as the presence of three criteria:
• Hyponatraemia >48 h;
• Serum osmolality <280 mOsm/kg;
• Serum sodium concentration <135 mmol/l.
Populations in the identified studies were not always clearly
defined, particularly in relation to the duration of chronic
hyponatraemia. For this reason, the inclusion criteria were
broadened to include studies where hyponatraemia of more than
48 h had not been explicitly reported, but in which chronic
hyponatraemia was a known feature of the chronic disease states
being assessed (e.g. SIADH or chronic uncontrolled heart fail-
ure) on the assumption of a chronic process. A protocol amend-
ment was recorded.
Randomized or quasi-randomized (i.e. trials in which the
methods of allocating people to a treatment arm were not ran-
dom, but were intended to produce similar groups11) controlled
trials published as full reports were eligible for review. Eligible
trials compared any degree of fluid restriction or any drug treat-
ments with the aim of increasing serum sodium concentration
in patients with chronic nonhypovolaemic hypotonic hypona-
traemia. Outcomes of interest to the review included: all-cause
mortality, health-related quality of life outcomes, length of hos-
pital stay, response (an increase in serum sodium of ≥5 mmol/l
or normalization of serum sodium concentration (≥135–
145 mmol/l)), serum sodium concentration (mmol/l) at end of
treatment or change from beginning to end of treatment, out-
comes potentially related to over-correction of serum sodium
concentration or rapid increase in serum sodium (i.e. more
than 12 mmol/l in 24 h or more than 18 mmol/l in 48 h), any
treatment-specific side effects and treatment discontinuation.
Searches were conducted in MEDLINE, EMBASE, PubMed,
Cochrane Library, Science Citation Index, World Health Organi-
sation International Clinical Trials Registry Platform and clini-
caltrials.gov. Selected conference proceedings were searched. The
detailed search strategies are provided in the Appendix S1–S3.
Two independent reviewers screened the search results against
the eligibility criteria in the protocol. Any disagreements were
discussed with a third reviewer. Studies excluded following full-
text review are listed in the Appendix S1–S3.
Two independent reviewers conducted data extraction and
quality assessment. Details of the funding source, trial design
and methodology, patient characteristics, treatment and permit-
ted dose adjustments, statistical methods used and prespecified
outcomes (including the unit of measurement, analysis popula-
tion and effect size) were extracted. The Cochrane Assessment of
Risk of Bias tool11 was used to assess risk of bias at the study
level. High risk of bias was assumed if at least one quality crite-
rion was not adequately met.
The results of similar studies were statistically pooled using
both fixed-effects and random-effects models. RevMan (version
53) was used to calculate pairwise meta-analysis using standard
frequentist approaches.11
Studies were drawn from the published literature; therefore, the
effects being estimated in each study are likely to vary. There is
also a degree of heterogeneity among studies in how outcomes are
measured and in the ways that missing data were handled. Conse-
quently, we report the most appropriate meta-analysis model: the
random-effects model. Risk ratio (RR) has been used as a sum-
mary statistic (with 95% confidence intervals (CI)). RR has been
shown to be more understandable and easier to interpret.11
Statistical heterogeneity was assessed for each pairwise com-
parison informed by at least two trials. Forest plots assess
heterogeneity and present the I-squared statistic, between-study
variance (tau-squared) and the P-value of the heterogeneity
statistic Q. I-squared values of 25%, 50% and 75% were defined
as representing low, moderate and high heterogeneity.11
Following data extraction, an assessment of the studies identi-
fied, and after consultation with independent clinical experts, it
was agreed that in studies with more than one treatment group
receiving different doses of the same drug, the treatment groups
were collapsed into one single pairwise comparison versus
placebo.11
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It was also agreed that it was appropriate to combine data at
any time point after 4 days of treatment initiation, on the
understanding that the treatment effect of vaptans plateaus at
4 days and any additional treatment is effectively maintaining
this effect. For the change from baseline outcomes and for inci-
dence of response, some trials reported data at a number of time
points and the data were not always consistent over time. Where
this was the case, data for all time points are reported and the
trials are grouped by similar time point for the meta-analyses. A
post hoc ‘end-point’ analysis, (i.e. meta-analysis including the
end of study data for each trial) was also conducted for these
outcomes.
We planned to analyse publication bias using funnel plots.11
Subgroup analyses were prespecified in relation to the underly-
ing condition associated with hyponatraemia. Sensitivity analyses
were explored for each meta-analysis excluding the following
trials in turn:
• Average serum sodium concentration at baseline
>130 mmol/l;
• >50 patients per treatment arm to explore how larger trials
influence the results;
• Imposed mandatory fluid restriction;
• High risk of bias;
• Non-English language studies;
• Unpublished studies;
• Industry funding;
• Based on country;
• Based on diagnostic criteria.
The primary meta-analyses for each comparison include all
eligible trials that reported data for that outcome, regardless of
underlying condition. Results of the SIADH and cancer sub-
groups are also reported here, where data were available.
Results
The searches retrieved 45 716 records. Following study selec-
tion (Fig. 1), 18 trials met the eligibility criteria or reported
data for an eligible subgroup. Two trials assessed conivap-
tan,13,14 four assessed lixivaptan,15–18 three assessed satavap-
tan19–21 and nine assessed tolvaptan.22–29 There were no RCTs
published assessing other known interventions such as urea,
sodium tablets or mannitol.
Fig. 1 Study selection process.
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We contacted the authors of ten studies and Otsuka, to seek
additional information about the trials’ design and outcomes.
Otsuka (manufacturer of tolvaptan and funder of this review)
provided information for six trials of tolvaptan vs placebo and
the authors of two further trials responded.14,20
A summary of the characteristics of the included trials is pre-
sented in Table 1. All 18 trials were randomized multicentre trials.
Seventeen were double-blind trials and reported to be placebo-
controlled. One trial was open label describing fluid restriction as
an active control.23 In two trials, the double-blind period was
followed by a 1-year open-label noncomparative extension with
flexible dosing: for this review, only results reported throughout
the double-blind period were extracted.19,21 All trials were sup-
ported or funded by pharmaceutical companies.
The underlying cause of hyponatraemia varied across the trials.
Some trials reported data for a specific population and others
included patients with various underlying causes. Three trials
assessed hyponatraemia in patients with SIADH,15,21,22 four
assessed hyponatraemia in patients with congestive heart fail-
ure,24–27 two assessed hyponatraemia in patients with cirrho-
sis,17,20 and one assessed hyponatraemia in patients with cancer.28
The other eight trials assessed hyponatraemia in patients with a
range of underlying conditions. In these trials, results were
reported for subgroups of patients in the Study of Ascending
Levels of Tolvaptan in hyponatraemia (SALT 1 and SALT 2) trials
with SIADH,30 cirrhosis,31 SIADH and cancer,32 and schizophre-
nia33; one trial reported some results for a subgroup of patients
with cirrhosis and SIADH18 and one trial reported some results
for a subgroup of patients with congestive heart failure (CHF).19
All trials reported assessing patients with nonhypovolaemic
hyponatraemia, but only five trials specifically reported patients’
fluid status. In two trials,15,16 all patients were categorized as
euvolaemic. In the other three trials, 50–70% of patients in each
treatment arm were euvolaemic and the remainder were hyper-
volaemic.13,14,29
Sixteen trials reported primary outcomes related to serum
sodium correction, serum sodium normalization or change from
baseline. Two trials reported weight change24,27 and worsening
heart failure27 as primary outcomes and reported results for the
hyponatraemia subgroup in a larger CHF population.27
The majority of trials used the last observation carried for-
ward (LOCF) method to impute missing data. LOCF can lead to
bias and is only appropriate in cases where a relatively recent
observation has been carried forward.11 The majority of trials
did not report this and therefore studies using this method of
imputation were categorized as having an unclear risk of bias.
Two trials had low risk of bias,14,20 five had high risk of
bias21,23,27,28 and 11 did not report adequate detail and were cat-
egorized as unclear risk of bias indicating that there is a substan-
tial risk of bias across the data set as a whole.
There were no significant differences between the fixed- and
random-effects results for any outcome assessed.
Results are shown in Tables 2 and 3. The I2 statistic presented
in the tables indicates the level of statistical heterogeneity for
each meta-analysis. All of the comparisons had low to moderate
levels of heterogeneity unless otherwise stated.
Response was defined in the protocol as an increase in serum
sodium of ≥5 mmol/l and/or normalization of serum sodium
concentration (≥135–145 mmol/l). A random-effects meta-analy-
sis suggests that patients randomized to lixivaptan,15–17 satavap-
tan19–21 and tolvaptan22,26,29 are significantly more likely to
experience a response compared to placebo, with tolvaptan
showing the largest treatment effect (RR 330 [197, 554]).
Tolvaptan data were available up to 30 days24,29 and in all cases
tolvaptan was significantly superior to placebo, with the excep-
tion of day 14.23,28 The trials at day 30 showed high levels of
heterogeneity (I2 = 74%). Results were similar for tolvaptan
compared to placebo when considering SIADH population/sub-
groups only at day 4.22,30
For the change in the daily area under the curve (AUC) of
serum sodium, in the random-effects meta-analyses, patients
randomized to lixivaptan at day 315,16 and tolvaptan at day
4,22,26,29 day 7,22,26 day 3029 and in the end of study analy-
sis22,26,29 had significantly greater changes in daily AUC com-
pared with placebo. Two trials of conivaptan did not show any
differences between conivaptan and placebo.13,14 Trials of coni-
vaptan at day 7 (I2 = 93%), and trials of tolvaptan (I2 = 77%)
showed high heterogeneity. Subgroup analysis in SIADH patients
also found a significantly greater change in daily AUC among
tolvaptan patients22,30 compared to placebo.
For the change in serum sodium, pooled analyses of conivap-
tan,13,14 lixivaptan,15–18 satavaptan19–21 and tolvaptan22–25,27–29
versus placebo all reported significantly greater changes in
patients randomized to vaptans. Trials assessing tolvaptan at
days 10–14 had high levels of heterogeneity (I2 = 75%).
There was no significant difference between patients receiving
any of the vaptans compared to placebo in single trials or
pooled analyses for mortality, treatment discontinuation and
incidence of hypernatraemia.
Four trials comparing tolvaptan and placebo documented the
incidence of osmotic demyelination syndrome.23,25,29 No inci-
dents were reported in either treatment arm by these trials.
A rapid increase in serum sodium was defined as an
increase of more than 12 mmol/l in 24 h or more than
18 mmol/l in 48 h. Pooled analyses of two trials of conivap-
tan13,14 and three trials of satavaptan19–21 found no differences
in the incidence of a rapid increase in serum sodium in
patients randomized to either intervention or placebo. While
there were no differences individually in the three tolvaptan
trials,23,29 when pooled, the incidence of a rapid rise in serum
sodium levels was significantly greater in patients randomized
to tolvaptan than placebo (RR 985 [95% CI: 127, 7635]
P = 003). However, because of the low number of events in
the treatment arm (5 and 4 events in SALT 1 and SALT 2,
respectively) and no events in the placebo arm of each trial,
the size of the treatment effect is uncertain. Gheorghaide
(2006) reported zero events in both treatment arms and did
not contribute to the meta-analysis.23
Few trials reported health-related quality of life and, those
that did, used various generic instruments none of which are
specifically designed to assess hyponatraemia (see Appendix S1–
S3). One trial of lixivaptan15 reported change from baseline in
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the Medical Outcomes Survey 6-item cognitive function scale;
higher scores indicated less impairment of cognitive functioning.
The trial was carried out in patients with SIADH. Data were
reported at weeks 8 and 12. At both time points, significantly
greater increases from baseline were observed in the lixivaptan
group compared with placebo.
The two SALT trials reported change from baseline in the
Short Form-12 mental health composite score (SF-12
MCS).18,19,34,35 At day 30 in SALT 1 and in the SIADH sub-
group of the two SALT trials, patients receiving tolvaptan had
a significantly greater increase in SF-12 MCS score compared
with patients receiving placebo. There was also a significant
difference in favour of tolvaptan when data were pooled for
the two SALT trials at day 30 mean difference: 476 (95% CI:
011 to 941).
With the exception of a greater incidence of serious adverse
events in patients receiving tolvaptan in the EVEREST trial,
which assessed the safety of tolvaptan 30 mg at 60 days in
patients with heart failure, there was no evidence of a difference
between any of the other treatments identified compared with
placebo for the incidence of adverse and serious adverse events
and withdrawal due to adverse events. Adverse event data could
not be pooled because of differences in the underlying condition
of patients across trials and the differences in the time point
assessed.
Comparative length of hospital stay could not be assessed
because of the different settings reported for the studies (some
studies required patients to be hospitalized for some or all of
the trial period, whereas others did not) and the variation in
underlying conditions.
None of the sensitivity analyses significantly altered the meta-
analyses results. Sensitivity analyses excluding unpublished stud-
ies were not undertaken because all of the included studies were
identified in the published literature. Sensitivity analyses exclud-
ing studies using the following filters were not explored: diag-
nostic criteria (too much variation across trials and differences
in underlying conditions), source of funding (all studies were
industry funded), country (insufficient variation to warrant
investigation).
We planned to analyse publication bias, but none of the analyses
had a sufficient number of studies to conduct funnel plot analysis.11
Discussion
This systematic review and meta-analysis identified RCT evidence
only for vaptans in the treatment of chronic nonhypovolaemic
hypotonic hyponatraemia. No RCTs or quasi-RCT evidence was
identified for any alternative interventional strategy. Vaptans are
more effective than placebo for the treatment of hyponatraemia
for outcomes related to serum sodium correction.
There was limited evidence on the impact of vaptans treating
hyponatraemia on other relevant outcomes, such as quality of
life. Patient-reported outcome measures were inconsistently and
infrequently assessed across trials and, therefore, conclusions
cannot be drawn regarding patients’ experiences of the different
vaptans.T
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There was no evidence of a difference between placebo and
any of the vaptans on mortality as an outcome but this was
not a primary outcome in the studies examined. A recent
review and meta-analysis36 found that improvements in serum
sodium, in hyponatraemic patients with a range of clinical con-
ditions, are associated with a reduction in overall mortality.
However, similar to other studies this observation does not
establish a cause–effect relationship but is hypothesis-generating.
The lack of correction might contribute directly to poor out-
comes or might be a biomarker for the severity of the underly-
ing comorbidities.
There is currently controversy regarding the optimal treatment
of hyponatraemia related to SIADH and the guidelines available
recommend a number of strategies to treat hyponatraemia.1,3,8
The guidance is clear that in the acute setting hyponatraemia
can be corrected relatively quickly without longer-term adverse
consequences. However, it is less clear in the chronic setting
(the presence of hyponatraemia >48 h). Similarly, severe
hyponatraemia in which neurological symptoms are apparent
requires intervention and most clinicians agree that hypertonic
saline to elevate the serum sodium to a safe level of greater than
120 mmol/l is appropriate; however, in mild to moderate
hyponatraemia as in the current analysis, optimal treatment
strategies are less clear.
The main goal of therapy for moderate to severe hypona-
traemia is to reliably increase the serum sodium concentration
and safely minimize the risk of the brain swelling and also to
improve hyponatraemic symptoms, while avoiding the devastat-
ing potential neurological sequelae caused by too rapid or too
great a correction of the sodium concentration. To date, no
therapy fulfilled these criteria; 3% saline improves serum
sodium, but nearly 10% of patients will experience excessive cor-
rection, as a result of water diuresis that occurs during therapy.
Some have advocated concomitant use of desmopressin to avoid
this potential complication, but evidence from RCTs is lacking.
Assessment of other parameters of patient-related outcomes is
lacking and requires further study.
Thus, despite the observation in clinical care that hypona-
traemia is the commonest occurring electrolyte disturbance, it is
striking that the only intervention for which there are any data
from RCTs are the vaptans. There are no data from RCTs on
the efficacy and safety of other commonly used interventions
such as oral urea tablets, salt tablets, hypertonic saline loop
diuretics, mannitol, demeclocycline or lithium.
Implications for practice and further research
recommendations
RCT evidence of the effectiveness of interventions to treat
hyponatraemia was identified for conivaptan, lixivaptan, tolvap-
tan and satavaptan. Our analysis suggests that the efficacy profile
across the vaptans is similar. Currently, tolvaptan has EU
approval for the treatment of hyponatraemia secondary to
SIADH and US approval for clinically significant nonhypo-
volaemic hyponatraemia (serum sodium <125 mEq/L or less).
Satavaptan was withdrawn from the European Medicines Agency
in 2008,37 lixivaptan is not licensed, and conivaptan (IV) is
approved for the treatment of euvolaemic hyponatraemia in hos-
pitalized patients only in the United States.
Clinically the question remains regarding the relevance of
the evolution and aetiology of hyponatraemia in different con-
ditions; that is, is the hyponatraemia a “primary” feature in
euvolaemic disorders which are often due to SIADH, or is it a
“secondary” and variable feature, as seen in patients with heart
failure, nephrotic syndrome and/or liver disease where there is
often hypervolaemia. This is a complex concept but where the
hyponatraemia is predominantly a secondary feature, the out-
comes should be assessed as those of the underlying disease
processes. Thus, management of the heart failure for example
should lead to improved sodium levels. In the case where the
intervention is for a “primary” feature such as in SIADH
which responds to specific treatment to improve serum sodium
such as fluid restriction or vaptans, the rate of change in
serum sodium can be used as a surrogate biomarker of out-
come of this therapy, particularly if there are no suggestions of
adverse outcomes. It, however, is not a marker of overall out-
come from the underlying disorder such as neoplasm or pneu-
monia which will be dictated by specific more prolonged
therapy if feasible.
Thus, for future studies treating hyponatraemia we recom-
mend standard measurement criteria of clinical status at inclu-
sion. These measures should include the clinical hydration state,
co-prescribed medications, nadir sodium levels and presence/ab-
sence of cognitive or other symptoms/signs associated with
hyponatraemia. They should also include the underlying pathol-
ogy for “secondary” hyponatraemia where known, and the pre-
treatment plasma/urine osmolalities and electrolytes that should
be common to all studies. Further, a standard set of outcome
measures should be agreed in relation to the sodium change and
primary disease state. Such criteria are necessary to co-ordinate
clinical research to facilitate a future clinical consensus in this
complex but relatively common area of clinical practice, which
is made more challenging because it intersects multiple medical
and surgical specialties as well as primary care.
Recent clinical guidelines suggest that individualized care is
optimal for treating patients. Tolerability is also a key compo-
nent to effective therapy. There were little data available to
determine which specific subgroups of patients might benefit
from treatment with a vaptan and no data available on which
patients would benefit from other interventions suggested in
clinical guidelines.
All of the studies identified in this review were placebo-con-
trolled trials. In the absence of direct evidence of the relative
efficacy of vaptans for chronic nonhypovolaemic hypotonic
hyponatraemia, there is potential for indirect treatment compar-
isons. Well-conducted RCTs comparing relevant comparators in
use in current practice, such as vaptans, fluid restriction, urea,
sodium tablets or hypertonic saline solution are required, to
gain more evidence on the comparative effectiveness of different
treatments and to explore which subgroups might benefit most
from individual treatments. This will allow further revision of
clinical guidelines.
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This review was informed by extensive searches to ensure that
as many relevant studies as possible were identified. None of the
comparisons in these analyses had sufficient studies to assess
publication bias reliably using funnel plots.
This review has benefited from the provision of additional
data for six trials of tolvaptan,34–39 one of conivaptan14 and one
of satavaptan.20 Authors of the other studies did not provide
similar data: we do not know how that missing data might
impact on the risk of bias assessment or results.
This review considered all doses of each vaptan together and col-
lapsed doses into a single treatment arm. This approach assumes
that all doses of a drug have a similar treatment effect, which may
not always be the case. The majority of trials adopted an approach
allowing titration and dose adjustments at set points in the trial
which may be more reflective of clinical practice. While there were
some differences in the permitted dose adjustments and fluid
restriction across trials, these differences were considered unlikely
to impact on the overall treatment effect. Trials with mandatory
fluid restriction were excluded from the meta-analyses in a sensitiv-
ity analysis and this had little impact on the treatment effect.
Flaws in the design, conduct and analysis of RCTs can lead
to bias and raise questions about the validity of their findings.
The trials in this review varied in design and quality; however,
a sensitivity analysis excluding high risk of bias studies did not
have a great impact on the direction or significance of the
results. This review did not consider other types of evidence
such as case series and case reports which may provide addi-
tional information, particularly in relation to safety and the les-
ser reported adverse events which may be under-estimated in
published RCTs.
The trials varied in terms of the underlying causes of hypona-
traemia. Some studies assessed a mixed population (i.e. any
underlying cause), while others assessed hyponatraemia in speci-
fic populations of patients with heart failure, cirrhosis or
SIADH. Where possible, subgroup analyses were also carried out
by underlying condition.
Conclusions regarding the safety of each treatment should be
drawn with care and should take into consideration the varying
assessment time points and different underlying conditions.
Conclusions
Vaptans are an evidence-based treatment to increase serum
sodium in patients with nonhypovolaemic hyponatraemia. The
RCT evidence indicates that each of the vaptans significantly
improves serum sodium concentration compared with placebo
and is associated with greater rates of response than placebo.
There was no evidence of a difference between any of the vap-
tans compared with placebo for mortality, discontinuation and
rates of hypernatraemia; however, higher rates of a rapid
increase in serum sodium were observed in the tolvaptan-treated
patients in the pooled analysis. RCTs are required to determine
the comparative efficacy of vaptans, fluid restriction and the
other treatments currently used in clinical practice or recom-
mended in guidelines for chronic hypotonic nonhypovolaemic
hyponatraemia.
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